ResearchSafe

Rapamycin (Rapamycin (Sirolimus))

Category: Anti-Aging. Status: FDA-approved (off-label for longevity).

An mTOR inhibitor originally used as an immunosuppressant, now the most studied pharmaceutical longevity compound. Low-dose pulsed rapamycin is prescribed by longevity telemedicine clinics for its anti-aging and immune-rejuvenating properties.

How it works

Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level.

Key facts

  • Molecular weight: 914.17 Da
  • Half-life: ~62 hours
  • Bioavailability: ~14% oral
  • Storage: Room temperature.

Dosing overview

  • Typical dose: 3-6 mg
  • Frequency: Once weekly
  • Duration: Ongoing (pulsed)
  • Route: Oral tablet

Protocol notes

  • Longevity protocols use low, pulsed dosing - commonly ~5-6 mg once weekly (not the daily transplant doses).
  • Some start at ~3 mg weekly and titrate up based on tolerance and side effects (mouth sores, lipids).
  • Weekly pulsing is designed to inhibit mTORC1 transiently while sparing immune-suppressing mTORC2 effects.

Reported benefits

  • Enhanced autophagy
  • Immune rejuvenation
  • Anti-aging cellular effects
  • Cancer risk reduction
  • Improved vaccine response (elderly)
  • Longevity extension

Possible side effects

  • Mouth sores
  • Impaired wound healing
  • Elevated lipids
  • Immunosuppression (at high doses)
  • GI upset

Research

  • Low-dose rapamycin in human aging (2023): Weekly rapamycin improved immune function in elderly adults with 40% better vaccine response and no clinically significant immunosuppression.
  • mTOR inhibition and lifespan extension (2022): Pulsed rapamycin extended median lifespan by 20-26% in multiple mammalian models across both sexes.

Compare Rapamycin

Community discussions about Rapamycin

Research and educational reference only. Not medical advice.